Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M125,019Revenue $M34,858Net Margin (%)12.0Z-Score2.2
Enterprise Value $M295,916EPS $1.7Operating Margin %15.6F-Score5
P/E(ttm))27.1Cash Flow Per Share $0Pre-tax Margin (%)12.9Higher ROA y-yN
Price/Book19.210-y EBITDA Growth Rate %0.5Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.35-y EBITDA Growth Rate %-5.1Current Ratio1.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-43.6ROA % (ttm)6.8Higher Current Ratio y-yN
Dividend Yield %5.6Insider Buy (3m)0ROE % (ttm)47.5Less Shares Outstanding y-yY
Payout Ratio %141Shares Outstanding M2,678ROI % (ttm)14.0Gross Margin Increase y-yY

Gurus Latest Trades with GSK

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKDodge & Cox 2014-12-31 Reduce-0.64%$41.3 - $47.14
($44.76)
$ 46.153%Reduce -37.91%23,959,301
GSKHOTCHKIS & WILEY 2014-12-31 Add0.21%$41.3 - $47.14
($44.76)
$ 46.153%Add 13.04%12,213,885
GSKDavid Dreman 2014-12-31 Sold Out -0.01%$41.3 - $47.14
($44.77)
$ 46.153%Sold Out0
GSKDodge & Cox 2014-09-30 Reduce-1.11%$46.29 - $54.52
($49.01)
$ 46.15-6%Reduce -35.93%38,589,161
GSKHOTCHKIS & WILEY 2014-09-30 Add0.98%$46.29 - $54.52
($49.01)
$ 46.15-6%Add 118.31%10,804,564
GSKCharles Brandes 2014-09-30 Add0.56%$46.29 - $54.52
($49.01)
$ 46.15-6%Add 36.63%3,415,717
GSKIrving Kahn 2014-09-30 Buy 0.38%$46.29 - $54.52
($49.01)
$ 46.15-6%New holding51,000
GSKNWQ Managers 2014-09-30 Add0.03%$46.29 - $54.52
($49.01)
$ 46.15-6%Add 39.82%208,125
GSKDavid Dreman 2014-09-30 Buy 0.01%$46.29 - $54.52
($49.01)
$ 46.15-6%New holding1,328
GSKHOTCHKIS & WILEY 2014-06-30 Add0.93%$51.55 - $56.39
($54.16)
$ 46.15-17%Add 13358.60%4,949,118
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 46.15-17%Reduce -43.82%5,156,449
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 46.15-17%Add 15.52%2,500,048
GSKJohn Rogers 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 46.15-17%Add 49.33%988,772
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 46.15-17%New holding270,900
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 46.15-17%Reduce -23.61%323,500
GSKJohn Rogers 2014-03-31 Add0.16%$50.9 - $56.66
($54.07)
$ 46.15-17%Add 57.21%662,150
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 46.15-17%Sold Out0
GSKNWQ Managers 2014-03-31 Reduce-0.03%$50.9 - $56.66
($54.07)
$ 46.15-17%Reduce -28.91%148,800
GSKHOTCHKIS & WILEY 2014-03-31 Buy 0.01%$50.9 - $56.66
($54.07)
$ 46.15-17%New holding36,773
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 46.15-12%Add 1702.13%423,500
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$22112.09view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.14120.72view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29782.04view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12288.83view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14233.29view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12288.83view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      British Stock Picks From Gurus During Q4 Mar 24 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Bestinfond Adds More Than a Dozen Foreign Stocks to Portfolio Mar 06 2015 
      Causeway International Value Fund Adds 2 New Stocks Mar 03 2015 
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      Bestinfond's Top 5 New Buys During Q4 Feb 03 2015 
      Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
      Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 
      Gilead Sciences Still has More Upside Jan 22 2015 


      More From Other Websites
      Even After Recent Gains, AstraZeneca plc And GlaxoSmithKline plc Are Still Cheap! Mar 27 2015
      Two Experimental Ebola Vaccines Show Promise Mar 26 2015
      Two experimental Ebola vaccines pass safety test in African trial Mar 26 2015
      Two experimental Ebola vaccines pass safety test in African trial Mar 26 2015
      Two experimental Ebola vaccines pass safety test in African trial Mar 26 2015
      Actavis takes 'specialty pharma' route to health Mar 26 2015
      What Could Go Seriously Wrong With Aviva plc, NEXT plc, GlaxoSmithKline plc & Standard Chartered PLC Mar 26 2015
      GSK receives approval for Encruse® Ellipta® in Japan for the treatment of COPD Mar 26 2015
      Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
      Veeva (VEEV) OpenKey: A Key to Customer Data Referencing - Analyst Blog Mar 25 2015
      From Snitch Pill to Xbox Sensors, Novartis Goes Digital Mar 25 2015
      3 Neil Woodford High-Income Blue Chips For Your ISA: GlaxoSmithKline plc, SSE PLC And Legal &... Mar 25 2015
      From Pills That Snitch to Xbox Sensors, Drugmaker Goes High Tech Mar 24 2015
      Stocks to Cure What Ails on World TB Day - Analyst Blog Mar 24 2015
      Agenus Boosted by Big Pharma Deals Mar 24 2015
      GSK’s 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics... Mar 24 2015
      TG Therapeutics Is A Best Idea Mar 24 2015
      My ISA Watch List: Whitbread plc, GlaxoSmithKline plc And Dignity Plc Mar 24 2015
      3 Stocks To Avoid For Your 2015 ISA: Barclays PLC, Lloyds Banking Group plc & AstraZeneca plc Mar 24 2015
      Biogen downgrade, Pfizer rises Mar 23 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK